• Lead: Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder

  • Oct 29 2024
  • Length: 5 mins
  • Podcast

Lead: Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder

Listen for free

View show details

  • Summary

  • Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder

    JAMA Network

    This population-based retrospective cohort study assessed whether the use of buprenorphine/naloxone is associated with lower risk of treatment discontinuation and mortality compared with methadone. It included 30,891 individuals initiating treatment for the first time during the study period and found that the risk of treatment discontinuation was higher among recipients of buprenorphine/naloxone compared with methadone (88.8% vs 81.5% within 24 months). The risk of mortality was low while in either form of treatment (0.08% vs 0.13%). Individuals receiving methadone had a lower risk of treatment discontinuation compared with those who received buprenorphine/naloxone. The risk of mortality while receiving treatment was similar between medications.

    Read this issue of the ASAM Weekly

    Subscribe to the ASAM Weekly

    Visit ASAM
    Show more Show less
Show more Show less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about Lead: Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available